ASH

Good day. Thank you for standing by. Welcome to the Ashland third quarter conference earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a Q&A session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Sandy Klugman, Director of Investor Relations. Thank you, Sandy.

Thank you. Hello, everyone. Welcome to Ashland's third quarter fiscal year 2026 earnings conference call and webcast. My name is Sandy Klugman. I am Ashland's Director of Investor Relations. Joining me on the call today are Guillermo Novo, Chair and CEO, William Whitaker, CFO, as well as our business unit leaders, Alessandra Faccin, Life Sciences and Intermediates, Jim Minicucci, Personal Care, and Dago Caceres, Specialty Additives. Please note that we will be referencing slides during today's call. We encourage you to follow along with the webcast materials available at ashland.com under Investor Relations. Please turn to slide two. As a reminder, today's presentation contains forward-looking statements regarding our fiscal 2026 outlook and other matters as detailed on slide two and in our Form 10-Q. These statements are subject to risks and uncertainties that could cause future results to differ materially from today's projections.

We believe any such statements are based on reasonable assumptions. There's no assurance these expectations will be achieved. We will also reference certain adjusted financial metrics, both actual and projected, which are non-GAAP measures. We present these adjusted figures to provide additional insight into our ongoing business performance. GAAP reconciliations are available on our website in the appendix of these slides. I'll now hand the call over to Guillermo for his opening remarks.

Thanks, Sandy. Welcome to everyone joining us. Please turn to slide five. Overall, we delivered a strong third quarter that reflected strong demand, disciplined commercial execution, and healthy free cash flow generation. Sales increased across all business units. Our performance was in line with the expectations we outlined at the beginning of the quarter. These results reflect the team's strong execution and reinforce the momentum we are building across the businesses. Life Sciences delivered double-digit sales growth, benefiting from broad contributions across pharma end markets and ongoing momentum within our globalized and innovate strategies. Pharma achieved its fifth consecutive quarter of volume growth, supported by strength in high-purity excipients, injectables, and innovation growth momentum. Personal Care generated another quarter of solid performance, led by biofunctional actives, high single-digits growth in skincare, and favorable contributions from hair care and Microbial Protection.

Performance reflected healthy growth across end markets and major regions, supported by strong customer engagement and innovation adoption. Specialty Additives delivered encouraging sales growth in line with our expectations. Strength in coatings and performance specialties was primarily driven by market share gains, reflecting strong commercial execution by the team. Regionally, most markets improved compared to prior year. Intermediates delivered higher sales, supported by improving merchant sales, driven by higher NMP demand in North America, EV battery, and energy storage applications. Operationally, our third quarter results reflected continued progress on manufacturing performance with further opportunities to improve. We remain focused on targeted investments and disciplined execution and expect continued progress in the fourth quarter as the benefits of these actions build.

We also generated strong cash flow during the quarter through disciplined working capital management and ended the quarter with a net leverage of 2.4x, returning to our long-term target range and strengthening our ability to invest in growth and innovation. Please turn to slide six. Our results demonstrated the strength of our execution and the benefit of the actions we have taken across the portfolio. Sales increased 7% year-over-year, reflecting broad-based growth across the portfolio. Profitability was impacted by production challenges encountered earlier in the fiscal year. Results improved sequentially and were largely in line with our expectations. We continued to make steady progress across the manufacturing network and on our strategic priorities. Our teams remain focused on commercial execution, pricing realization, and cost discipline. Pricing actions continued to gain traction, offsetting higher raw material costs while maintaining strong customer relationships. Please turn to slide seven.

Slide seven illustrates the breadth of our growth and the quality of our earnings profile. First, our consumer-focused businesses, Life Sciences and Personal Care, continue to generate attractive margins supported by resilient demand, innovation, and favorable mix. Second, Innovate and Globalize strategies continue to deliver measurable results with accelerated momentum in higher value application across the portfolio. Through the first nine months of the year, Innovate has exceeded its full-year target, while Globalize has already achieved its full-year target and continues to deliver strong results across the platforms. Third, while margins continue to reflect earlier production rate challenges and cost pressures, the actions we have taken across pricing, manufacturing, and commercial executions continue to gain traction. As a result, we are well-positioned for further profitability improvement in the fourth quarter.

Before turning the call over to William, I also want to take a moment to share that yesterday we announced a cooperation agreement with Ancora, an Ashland shareholder, with whom we have had constructive dialogue. Under this agreement, we are welcoming Peter Thomas and Allen Spizzo to the Ashland board as independent directors. Both bring significant executive and financial experience in specialty chemicals, and we believe their perspectives will support our continued focus on creating value for our shareholders. The board is also forming a capital allocation advisory committee to bring additional rigor and objectivity to our capital allocation strategy and planning. We value ongoing engagement with our shareholders and look forward to working collaboratively with Peter, Allen, and the rest of the board as we continue to execute our strategy. Let me leave you with three key takeaways before we get into the financials.

Demand remained healthy across our core businesses. Our innovate and globalize initiatives continue to generate meaningful growth, and we continue to make progress in addressing the operational challenges we have discussed throughout the year. These are encouraging signs for the business and reinforce our confidence in the opportunities ahead. Now I'd like to turn over the call to William to provide a more detailed view of the third quarter financial performance. William?

Thank you, Guillermo. Please turn to slide nine. Third quarter sales were $497 million, up 7% versus the prior year, driven primarily by volume growth across all business units. Volumes increased 6% across the portfolio, led by continued strength in Life Sciences and Personal Care, while Specialty Additives returned to growth and Intermediates benefited from improving merchant demand. Pricing increased approximately 1% year-over-year, led by Life Sciences and Specialty Additives, reflecting sequential improvement of approximately 300 basis points. Foreign exchange contributed approximately $3 million, or 1%, to sales. Adjusted EBITDA was $109 million, compared to $113 million in the prior year quarter. Growth in Life Sciences and Personal Care was more than offset by lower earnings in Specialty Additives and Intermediates.

Profitability continued to reflect the impact of lower production rates earlier in the year and the normalization of incentive compensation from a low base in the prior year. These factors were partially offset by higher volumes, favorable mix, and pricing actions. Sequentially, profitability improved as operating performance gradually improved and commercial actions gained traction across the portfolio. We expect a further step-up in profitability during the fourth quarter. Adjusted EBITDA margin was 21.9%, compared to 24.4% in the prior year quarter, reflecting these dynamics. Adjusted earnings per share, excluding amortization expense, was $1.02 compared to $1.04 in the prior year quarter. Cash generation remained a significant strength during the quarter. Ongoing free cash flow totaled $103 million, compared with $108 million in the prior year quarter, or representing a conversion above 90%.

Inventory is down nearly $80 million fiscal year to date, supporting strong cash generation and positioning us for improved absorption and reduced inventory-related margin headwinds going forward. We ended the quarter with $936 million of available liquidity and net leverage of 2.4x, returning to our long-term target range. During the quarter, we also refinanced our credit agreement, extending maturities on attractive terms and further strengthening our financial flexibility. The balance sheet remains a competitive advantage, providing flexibility to support operations, invest in strategic priorities, and maintain disciplined capital allocation. With that, I'll turn the call over to our business unit leaders for a closer look at segment performance. Alessandra, over to you for Life Sciences.

Thank you, William. Good morning, everyone. Please turn to slide 10 for Life Sciences. Life Sciences delivered another strong quarter, with sales up $180 million, up 11% versus the prior year period. Performance was driven by higher sales volumes, led by broad-based strength across pharma applications. Pharma achieved double-digit sales growth and delivered its sixth consecutive quarter of year-over-year volume gains. Demand remained healthy across all regions and product categories, including continued strength in high-purity excipients and injectables. We also benefit from customer order timing and supply chain normalization during the quarter. Adjusting for those factors, underlying demand trends remain strong and consistent with our expectations. Pricing contributed positively to results as commercial actions began to gain traction during the quarter with full run rate realization expected in the fourth quarter. Foreign exchange contributed approximately $1 million to sales during the quarter.

Injectables continued to outperform in the third quarter, delivering exceptional growth aligned with our globalized strategy. Performance was driven by the accelerating adoption of Ashland's high-purity differentiated excipient portfolio. Strong customer demand, a growing development pipeline, and increasing new product adoption support a strong outlook. We also announced the groundbreaking of our new tablet coating manufacturing facility in India, another important step in our globalized strategy. Following recent investments in Brazil, this expansion continues to strengthen our regional manufacturing footprint and position us to better serve customers in some of the fastest-growing pharma markets in the world. Turning to innovation, our recently launched products continue to drive above-market growth, led by low-nitrite oral solid dosage excipients and high-purity injectable and bioprocessing products. Strong customer adoption validates Ashland's strategy of investing in differentiated technologies that address increasingly complex formulation and regulatory requirements.

Turning to profitability, adjusted EBITDA increased 11% to $60 million compared to $54 million in the prior year quarter. Adjusted EBITDA margin was 33%, consistent with the prior year. Increased volumes, favorable pricing, and product mix offset the impact of lower production rates and higher SARD expense. Volume growth remained a primary driver of earnings improvement, while disciplined commercial execution and favorable mix also contributed to results. As we look ahead, Life Sciences continues to benefit from resilient pharmaceutical demand and increasing traction from our globalized and innovative strategies. Combined with pricing realization and ongoing innovation adoption, this trend supports our confidence in the long-term opportunities ahead. Please turn to slide 11 for Intermediates. Intermediates delivered a solid quarter with sales of $37 million, up 12% versus the prior year period, driven by improved merchant demand.

Merchant sales increased to $26 million from $23 million in the prior year quarter, supported by higher NMP demand from North American EV battery and energy storage customers ahead of planned fourth quarter shutdowns. Captive BDO sales were $11 million, up modestly from the prior year, reflecting stable internal demand and market-based transfer pricing. Foreign currency had a negligible impact on sales during the quarter. Turning to profitability, adjusted EBITDA was $4 million compared to $7 million in the prior year quarter. The year-over-year decline primarily reflected lower advanced manufacturing tax credits benefits compared to the prior year quarter, while underlying operating performance remained relatively stable. Pricing realization and improving demand in electronics, a key merchant application, helped offset a portion of this headwind during the quarter.

While conditions across the broader BDO value chain remain below historical levels, we are seeing soft yet encouraging improvement in NMP demand, mostly for energy storage-related applications. Given the volatility we have experienced in this market, we remain measured in our near-term outlook. However, our long-term view remains unchanged, and we continue to believe EV battery and energy storage applications represent an attractive growth opportunity for the business. I will turn the call over to Jim to discuss Personal Care.

Thank you, Alessandra. I'll now highlight our Personal Care results. Please turn to slide 12 for Personal Care. Personal Care delivered another quarter of growth, reflecting broad-based performance across end markets and continued strength in our higher-value applications. Sales were $155 million, up 5% year-over-year, driven by robust volume growth across the portfolio, new commercial wins, and favorable mix. Biofunctional Actives delivered another quarter of double-digit growth, supported by an expanding customer base. Collapeptyl continues to experience accelerated adoption due to its multifunctional benefits and ability to instantly improve skin radiance, hydration, elasticity, and provide visible wrinkle correction. Building on this momentum, Biofunctional Actives is also starting to see early commercial wins with Eternyte, our 2026 flagship ingredient. Microbial Protection also delivered solid growth, driven by double-digit volume gains across all regions.

In the third quarter, we inaugurated and commissioned our new Microbial Protection production facility in Europe. This investment strengthens our regional manufacturing capabilities, improves supply chain resilience in the region, and represents another major step in globalizing Microbial Protection. Within care ingredients, the portfolio delivered solid gains with positive momentum across hair and skincare markets. Overall, skincare delivered high single-digit growth, haircare delivered mid-single-digit growth, and oral and home care generated low single-digit growth. On a regional basis, growth was led by the Americas and China. Pricing improved sequentially as commercial actions continued to gain traction during the quarter while modestly below prior year. To clarify on pricing, price actions more than offset cost inflation. Specifically, in Microbial Protection, our globalized investments have reduced our cost structure, enabling share gains. Foreign currency contributed approximately $1 million to segment sales. Turning to innovation.

In the third quarter, we successfully executed our first industrial production of Multifunctional Starch, marking a pivotal step toward our planned calendar 2026 launch. Personal Care continues to make strong progress across our globalized and innovate strategies, supported by strong customer engagement and innovation focus. Turning to profitability. Adjusted EBITDA increased to $45 million from $41 million in the prior year quarter, and EBITDA margin expanded 110 basis points to 29%, reflecting broad-based growth across all business lines. Improved profitability was driven by higher sales volume and favorable product mix. In summary, Personal Care delivered both mid-single-digit growth and margin expansion in the quarter, demonstrating disciplined execution, strong customer focus, and continued adoption of differentiated and innovative technologies. With that, I'll turn the call over to Dago to review the results of Specialty Additives.

Thank you, Jim. Please turn to slide 13. Specialty Additives delivered sales growth in the quarter despite continued mixed demand conditions across end markets and regions. Sales increased 4% year-over-year to $136 million, driven by share gains, pricing realization, and strong commercial execution in Coatings and Performance Specialties, our most strategic industrial segments. Coatings recovery was driven by higher volumes from share gains across all regions, successful innovation implementation, and pricing discipline. Performance Specialties also delivered year-over-year growth, supported by favorable demand trends and commercial execution. These gains were partially offset by continued weakness in construction and energy and resources, where market conditions remained challenged and generally consistent with recent trends. Construction volumes continue to reflect both softer end market demand and the impact of deliberate portfolio management actions to preferentially serve more attractive regulated segments.

Regionally, growth was broad-based, with nearly every region delivering year-over-year improvement. Worth highlighting is that Middle East, Africa, India, and China delivered growth despite challenging market conditions and supply chain disruptions. Pricing actions continued to gain traction during the quarter. Together with favorable product mix, supported growth despite a muted demand environment. Foreign exchange contributed approximately $1 million to sales. Turning to profitability, adjusted EBITDA was $20 million compared to $26 million in the prior year quarter, while adjusted EBITDA margin was 14.7% compared to 19.8% in the prior year quarter. The results were generally in line with expectations and reflected lower fixed cost absorption associated with earlier operational challenges and reduced production rates at our Hopewell facility. These headwinds were partially offset by favorable pricing and product mix.

From an operational standpoint, we successfully completed the planned turnaround at our Hopewell facility and implemented a number of process control, productivity, and operational robustness improvements. While we are encouraged by the trajectory, we view this as an operational improvement journey to achieve our long-term productivity targets. The performance of our broader cellulosic asset base remains solid. We are leveraging our unique global manufacturing network to increase supply flexibility, optimize production, and strengthen overall supply reliability. We are also making solid progress across our balanced innovation portfolio, from regional solutions designed for local customer needs, to core innovations that strengthen and expand our existing product lines, to transformative technologies such as our novel additives, which continue to advance toward commercialization and represents a significant long-term growth opportunity for Ashland. Overall, while end market conditions remain mixed, we are encouraged by the progress being made across the business.

Continued price realization, strong commercial execution, and ongoing operational improvements support our expectation for improved profitability over time. I would like to recognize the team's strong execution and customer focus in what remains a challenging market environment. With that, I'll turn the call back to William.

Thanks, Dago. Please turn to slide 15. Let me briefly update you on our Execute strategy and manufacturing optimization initiatives. As Dago just discussed, progress across our HEC network optimization has been slower than originally planned. That said, the quarter unfolded largely as expected, operating performance improved, and we continued to advance the actions needed to improve productivity, reliability, and network performance. Beyond HEC, our manufacturing optimization initiatives remain on track. VP&D optimization efforts are now expected to deliver approximately $12 million of benefits this fiscal year. We also completed the final phase of our small plant consolidation initiative during the third quarter, delivering approximately $3 million of EBITDA benefit this year and further simplifying our manufacturing footprint. In total, VP&D optimization and small plant consolidation are expected to deliver $15 million this year.

Importantly, these are structural run rate savings rather than one-time gains, they position us to enter next year with a leaner, more competitive cost base. Execute remains a core component of our strategy. While we still have work to do, the broader portfolio of manufacturing initiatives is delivering results, we remain confident in the long-term value and profitability improvement these actions can generate. Please turn to slide 16. Our Globalize and Innovate initiatives continue to generate meaningful results and remain an important driver of growth across the portfolio. Through the first nine months of the fiscal year, Globalize has already achieved its full-year growth target, with Innovate having exceeded its full-year objective. Innovation highlights include continued momentum and high purity excipients within Life Sciences, skin longevity technologies and Personal Care, and formulated rheology solutions for stone paint within Specialty Additives.

As you heard from Alessandra and Jim, we are seeing tangible returns from the investments we have made to expand capabilities and strengthen our regional presence. These initiatives are increasing our exposure to higher value applications, strengthening customer relationships, and improving quality and durability of our growth profile. Just as important, the opportunity pipeline supporting both initiatives remains strong, reinforcing our confidence that Globalize and Innovate will remain meaningful contributors to growth and value creation in the years ahead. Please turn to slide 17. Turning to our outlook, which remains largely unchanged. We continue to see growth across the portfolio, ongoing momentum and higher value applications, increasing realization of pricing actions, and strong cash generation. We expect another step-up in profitability during the fourth quarter.

While operating performance remains below historical levels, the impact on profitability should be less pronounced than in the third quarter as operational trends improve and pricing actions continue to gain traction. As a result, we are reaffirming our fiscal 2026 sales and adjusted EBITDA guidance. We continue to expect sales of $1.835 billion-$1.87 billion and adjusted EBITDA of $385 million-$400 million. We are revising our adjusted EPS outlook to low to mid-single digit growth from mid to high single digit growth, reflecting a higher tax rate associated with unfavorable discrete items. We continue to expect ongoing free cash flow conversion of greater than 50% of adjusted EBITDA for the fiscal year. With that, I'll turn the call back over to Guillermo to discuss how our technology platforms are creating value across the portfolio before we open the line for questions. Guillermo?

Thank you, William, and please turn to slide 18. Innovation remains a core driver of Ashland's long-term value creation and an important differentiator across our portfolio. The progress we've made across our Globalize and Innovate strategy is a direct reflection of the strength of our technology platforms, customer partnerships, and R&D capabilities. We're very excited about the progress we're making on our new technology platforms. These new technologies have strong value propositions and target large, scalable growth opportunities. With strong customer engagement and validation, we feel very confident of the profitable growth potential of these platforms. With over 52 patents filed, they also present a great opportunity to build sustained differentiation. We're also expanding the range of products and applications these technology platforms can target. We're accelerating the commercialization of new products.

To provide investors with a deeper look at these opportunities, we will be hosting an innovation webinar on September 17th. During that event, we will provide additional insight into our innovation strategy, our progress in developing and commercializing them, and the opportunities we see to create long-term shareholder value. We believe these technology platforms represent a meaningful source of future growth, margin expansion, and value creation beyond our current planning horizon. Please turn to slide 19. As we conclude today's call, I'd like to reiterate what gives us confidence in the opportunities ahead. First, growth is returning across the portfolio. As the actions we have taken to optimize the business and improve the quality of our mix continue to gain traction, we delivered broad-based sales growth across all business units and regions, supported primarily by volume growth, strong customer engagement, and disciplined commercial execution.

We expect that momentum to continue through the fourth quarter. Second, we remain focused on disciplined pricing execution. Pricing actions are gaining traction across the portfolio, helping address cost inflation while maintaining strong customer relationships. I would also like to recognize the efforts of our team who have managed through a dynamic environment. Third, our Globalize and Innovate strategy is working. Globalize and Innovate continue to generate meaningful results, and we are seeing increased returns from the investments that we have made to expand our capabilities, strengthen our regional footprint, and accelerate growth in higher-value applications. This is the type of high-quality growth that enhances the long-term strength of our portfolio. Fourth, operational performance remains an area of focus. While we are not yet where we want to be, we are making progress and remain committed to improving our performance.

We continue to see meaningful opportunities to strengthen profitability as these efforts advance. Finally, we are extremely excited about the progress we are making on our new technology platforms. We look forward to sharing more about customer validation in the coming weeks, but we remain encouraged by the progress we are seeing across our innovation pipeline and the opportunities it creates across the portfolio. Ashland is a company with resilient end markets, leading technology positions, strong customer relationships, and a growing pipeline of innovation opportunities. The combination of improving demand trends, increasing pricing realization, advancing technology platforms, and ongoing operational improvements reinforces our confidence in the opportunities ahead. I'd like to thank our employees for their continued commitment and thank our shareholders for their ongoing support and engagement. Operator, please open the line for Q&A.

Thank you, Guillermo. At this time, we will conduct a Q&A session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from John McNulty with BMO Capital Markets. John, please go ahead.

Yeah, good morning. Thanks for taking my question. Wanted to get a better understanding of the pricing that you're seeing, and how we should be thinking about it going into 4Q and maybe early fiscal 2027. Do you expect it to largely accelerate from here? Is it going to vary depending on the segment, I guess? How should we be thinking about it and the realization of what you need to cover costs, raw material inflation, other inflation, et cetera?

Thanks, John, for the question. Let me first recap, just to remind everybody what all this inflation means to Ashland. We are not a petrochemical link anymore after we sold our adhesive business, so we have less exposure to petrochemicals and to high energy raw materials that require high energy for production. We're not immune. We do have some impact that we need to capture, but it's much lower. Don't expect the pricing movements that you see with commodity companies. Our intent is to recover inflation, maintain margins. We're a specialty company, additives company. Our focus is value pricing through the products, through the technology. That's how we expand. We don't use these moments to expand margins. We just want to make sure that we're holding it. That's sort of the basis. The team has executed very well.

We've captured all the inflation, both raw material and freight, and all the pricing we've implemented. Obviously, there's a flow-through effect. I think next quarter we'll see bigger benefits in terms of just the pricing ramp rate versus the inflation that we've already seen. We're basically covering everything that has impacted us, and you'll see that in the next quarter flowing through. After that, we'll see how markets evolve. Like in 2022, I think our focus is on moving fast so that we minimize the impact and maximize the benefits for us. The team has done that, so we feel very confident at this point. William, do you want to add anything else?

Just a couple other specifics. Thanks for the question, John. The important marker for us this quarter is that we swung from down 2% year-over-year in Q2 to up 1% in Q3. We expect that to continue. To Guillermo's point, sequential improvement Q4 as we get the pricing fully realized. In terms of order of magnitude, I'd expect that to be nearly as large as the sequential improvement we just saw in Q3. I think, overall, as you look to kind of pre-pricing actions to run rate exiting the year, it's going to be in line with

What Guillermo cited on the last earnings call of three to eight, it's going to be roughly, it depends by region, depends by product line, of course, but we're tracking roughly at the midpoint overall for the company.

Just one other point, John, that I want to make. In the prepared remarks, Jim made a comment just so that it doesn't get lost in the translation. For Personal Care, actually, they moved on pricing to recover raw materials. All that has gone through. I think the team has done a lot in terms of the globalize as we regionalize our businesses, our infrastructure manufacturing. We're changing our cost structure. That's allowed us a lot to do a lot of things. We're getting a lot of share. Jim, do you want to comment just to clarify, the quote, "lower pricing," is it really lower pricing in part of your business? If you could comment on that.

Thanks, Guillermo. Thanks, John. John, I think as William mentioned, sequentially, we're seeing an improvement and an increase in price. We took actions.

We worked through it in March when the conflict started. We started communicating with customers. The actions we've taken are price increases as opposed to surcharges, there's the flow-through that came through in the third quarter, but we took the necessary actions to cover the cost inflation in the majority of the portfolio. As we said, specifically in Microbial Protection, we just commissioned our facility in Europe. That's now the last step in globalizing the business. We now have assets in all regions to provide regional supply, that's really reduced our cost structure, and that's really enabled the share gains. That's a bit of a mix as you look at the overall price impact.

Okay, got it. That's all very helpful color. Just as the second question, can you speak to the manufacturing optimization, as well as Hopewell, which I guess is lumped into that. It sounds like you're seeing some decent progress, maybe not where you had hoped it would be originally, but seeing some decent progress there. How should we think about how you end your fiscal year and the tailwinds into 2027 from some of these optimization and cost out plans?

I think overall, I would differentiate the network optimization impact. I think if we look at the headwinds that we've had, there's two different types of things. What happened in Calvert City at the beginning, an equipment failure, that was the biggest impact, and the weather. I would put that on a side. If you actually look at the network optimization, what's worked well and where are some of the gaps that we're addressing now. Overall, it worked very well. If you look at our VP&D network, we're reducing costs, we've streamlined assets, we're getting much better productivity. I think it's still on the early stage. We're doing some cost optimization, but the real productivity work is going forward, so we still see the opportunity to further improve in those areas. All the small plant consolidation is done.

We just moved production units into our bigger sites so that we can leverage our overall cost structure. That is there. Specifically on HEC, it's two stories. We eliminated a plant, $25 million-$30 million are gone. Costs are out. I think how it's flowed through is two issues. Part of the benefit we're getting, it's not an upset anymore. We've used that to fill our plants in China. During this period of time as we executed, the market in China did go down, we've rebalanced the network, that we export now from China. You're seeing the benefit in terms of sustained margins and improvement, it wasn't a headwind for us. The rest of the things that are supposed to be more positive, I think really now it's a timing issue.

We made a shift in production of a different product mix that we brought to Hopewell. It's not just turn it on and start producing. It's different process technology. We've stopped the plant. We weren't getting the production rates that we wanted. We did a turnaround, as Dago mentioned. That turnaround's been successful. We've put in new equipment, process controls, that we can drive that productivity. It's just started up. It's running well. I think the product we're producing, the production rates are still not where we want them to be, and that's what we're working to ramp up. The benefit of that will take a quarter or two. It's not just when we hit the performance with recap and all that. It'll flow through into the P&L over time. That's the biggest issue that we have.

If I step back for the year, between the Calvert and weather and the Hopewell type situation, probably we lost about 200 basis points of margin. Overall, this year should have been 200 basis points higher, in terms of EBITDA and EBITDA margins, and that's the bogey that we want to start next year and try to make sure that we're in a good place.

Great. Thanks very much for the color.

Thank you so much. Please stand by for our next caller. Our next caller is David Begleiter from Deutsche Bank. Please go ahead. Your line is open.

Thank you. Good morning. Guillermo, just on the Q4 guidance, it's about a $15 million range. Is there a bias to, at this point in time, to either the midpoint or the upper end or the range as we sit here now?

Let me make a comment also. I'll have William comment on each of them. I think if you look at revenue and EBITDA, just at a high level, I would say on the revenue side, we feel really good. First, the markets are improving. The core markets have behaved resiliently, and they have been for a while. Our Personal Care, our Life Sciences, specifically pharma, are doing well. Our globalize and innovate is going well. We're getting all the pricing over inflation that we wanted to get. On the revenue side, the teams are focused, and the customer relationships are great. Even in uncertain times, we're performing well and feel confident. From my side personally, the revenue side, we feel very, very good about. I think in the EBITDA side, it's really about the operating performance.

We did communicate in the last call that we were having issues. I think from my side, I'm going to be more careful in terms of how much we want to promise the rate of improvement. One, because we got to drive that improvement over a period of time, and two, the flow-through, as we've talked about before, isn't straightforward. We want to make sure that we're a little bit more cautious on that side. William, do you want to make any comments?

Yeah. Hey, Dave. We intentionally didn't move the midpoint of the EBITDA guide. Just to give you some of the parts and pieces on our comfort there. One, to deliver the EBITDA midpoint, we will need stronger outcome on the sales range, and that's actually where our internal modeling does sit today. There's a few reasons we've been constructive. First of all, June was a strong exit, and then July and August order build are encouraging. As you heard from the team, Q3 was volume-led, and I'd expect Q4 to be more of a balanced delivery across both volume as well as some of the pricing actions we just spoke to. As you break it down by business, Life Sciences, I would expect quarter-over-quarter stability in terms of sales and earnings, which means, by the way, another solid and resilient quarter.

Personal Care, we do continue to see broad-based momentum both in sales mix and lifting margins. I'd say overall, and you heard in our prepared remarks, we are a bit more cautiously optimistic on the Specialty Additives side, but we are encouraged by the commercial execution of the team. Just to elaborate on Guillermo's point, I would say we're again cautiously optimistic on the manufacturing side. It's very much a key focus area for us. It's a real opportunity for improvement, and we do expect gradual progress in Q4. What's driving the margin lift into Q4? It's the pricing realization. It's continued momentum on the sales volume with a healthy mix. Globalize and innovate continues to be an outperformer for us year to date, and then gradual improvement on the operations side.

Very helpful. Guillermo, just on Globalize and Innovate, again, congrats on the success year-to-date. Any early thoughts on some targets for 2027 for Globalize and Innovate?

We'll update as we've done in the past. We want to be transparent on the progress that we're making, specifically Globalize. We've made a lot of investments. We just have a few that have come on stream, so we want to continue to spotlight our performance, not just for you, but internally, it also puts a lot more pressure with greater visibility on what we want to do. That's going well. On the innovation side, we're going to update in September. I think the biggest issue that we're looking at now, each of the businesses, I think Dago mentioned it in his comments.

We're getting a lot more traction, not just in the new technology platforms, but the businesses. Once you focus on innovation, it changes everybody's focused. There's a lot more work, even on the core innovation, creative new things that we're doing with new cellulosics and all that, modifying them in the different businesses. There's a lot more going on. We're going to probably expand over time, maybe not in September yet. It's not just new technology platforms. It's which are the scalable innovations that we really see an opportunity to drive growth, to drive margin expansion, and most importantly, is to drive differentiation. I think this is one of the challenges our industry is having of a hyper-competitive commoditization, all that kind of thing. I think driving that is going to be a critical area.

In September, we want to give you a little bit more color on what are the key technologies that are more scalable. What are the markets that we're targeting and dimensioning those markets, the potential. Obviously, the commitments, it's going to be a range. We want to make sure we show the pathway that we're taking, but these are all going to be scalable, and again, what excites me is it's a portfolio. It's not one project that we're vetting everything on. It's a number of exciting projects that have significant growth potential for a company our size.

Thank you.

Thank you.

Thank you. Our next question comes from Reed Halpert with Wolfe Research. Please go ahead. Your line is open.

This is actually Chris. Switching over to the Life Sciences segment, I would just like to drill down to the sustainability of the pharma volume growth. It seems like things have been picking up the last couple of quarters. You've been investing in both OSD as well as injectables. Is there anything on the horizon that kind of underscores a greater degree of conviction, specifically on the OSD side? Anything with GLP-1s, any new products? I know they can be smaller at times, but it seems like things are moving in the right direction. Thank you.

Chris, thanks for the question. Just a quick comment, and Alessandra, if you could comment, but the momentum in Life Sciences and specifically pharma is it's not innovational, but execute has been a very important part. Getting our cost structure, improving our competitiveness in our core businesses is a big area of focus. That gives us confidence that as the base business demand grows or stabilizes, that we're going to do well. Obviously, then there's a lot of the new innovations that the team is doing. Alessandra, you want to comment a little bit?

Yeah, definitely. Chris, just a comment. Overall, we target to grow at mid-single digits in Life Sciences, and that's what we expect for 2026. That's how we should look at that across the quarters. As Guillermo mentioned on OSD, oral solid dose, we saw VP&D stabilizing, so that's good. We also saw the momentum with our globalize and innovate strategies going very well with injectables, bioresorbable polymers, sugar, cellulosics. We are also excited with launches in other areas. The TVO and crop care, we are seeing the customer testings and feedback being positive. Not revenue yet in 2026, but that shows the momentum for going forward. When specific on your question about GLP-1, Ashland, it is benefiting and will benefit materially from the GLP-1 drugs growth that we are seeing.

We expect to see continued upside moving forward, both through the chemicals that are used on the API production as well as the excipients that are used in oral solid dosage. You see in the coming weeks, we are launching a permeation enhancer, and we are seeing the pre-launch momentum with customers. That's a launch that will happen in the month of August. Overall, we see the momentum from globalize, innovate, and then of course, in a stable market.

Finally, can you just comment on permeation enhancers? What is it for some of the investors that maybe aren't as familiar with that?

Yeah. Basically, with biologics, it helps with the absorption of the biologics and into an oral format. Basically, that's what we're launching in the month of August. As I mentioned, a good momentum with pre-launch sales already.

Got it. Just as a quick follow-up, similar question on Personal Care. Obviously, your portfolio's gone through a lot. There've been a lot of adjustments, restructurings, outages, which obviously have been distributed periodically throughout some of the segments. It seems like you're also building a decent amount of momentum here, specifically in skin and hair. I was kind of curious, in terms of your outlook there, how much of that is just a lack of destocking? Some of your customers have gone through their own restructurings, in some cases, several restructurings. Just in terms of your outlook and your degree of confidence in that portfolio, where do you stand versus the last six, 12, 18 months? Is this sustainable in fiscal 2027? If so, what's underscoring that the most? Thank you.

Hey, Chris. Thanks for the call. I think if you zoom out and you look at the year, right? In Q1, we had highlighted that there were some customer-specific outages that occurred mainly in North America. Adjusting for those, in Q1, we were low single-digit growth. In Q2, mid-single-digit growth. This quarter, again, mid-single-digit growth, all driven primarily, predominantly by volume. As we look into the next quarter, we expect to be in the same zip code, mid-single-digit growth. For the full year, we expect to land mid-single-digit versus prior year. I think we've built that momentum, right? If you look at biofunctional actives. In Q3, we delivered almost 30% growth in biofunctional actives. We've been very bullish on the technology. We have a great technology. What do we have to do?

We have to build the team, we have to build the pipeline, engage with customers, then convert that pipeline. That's exactly what's happening. That model is flowing through all of the business lines. Great technology. We built the team, we engaged with customers, we've built the pipeline, now we're starting to see the benefit of that. There is that lead time of building the pipeline, which we did last year. This year is really converting on that pipeline and it's coming through in the volume growth. I think the really exciting part is that it's broad-based, right? If you look at biofunctional actives, 30% growth in the quarter. We are both on trend with exosomes, PDRN, we're setting trends, and we're developing a new ingredient in biofunctional actives. We'll share a bit more.

We're still filing the IP on that, this is really going to be the next blockbuster hit in this segment. Microbial Protection, double-digit growth on a volume basis across all regions. Our investments are all in place now to globalize that business, regionalize our supply footprint. We're gaining share. In our care ingredients, we're doing really well with our guars, with our cellulosics, our VP&D. It's really broad-based, and we expect to continue to carry this momentum into next year.

Thank you very much.

Thank you.

Thank you.

Our next question comes from John Roberts with Mizuho Securities. Please go ahead. Your line is open.

Thank you. I believe the activists wanted Ashland to run a formal sales process. Was there an agreement to run a formal sales process, or is that still yet to be determined by the new committee of the board with the two new board members?

John, thanks for the question. Obviously, that's sort of the elephant in the room that everybody's asking about. Look, first and foremost, our team is focused on driving the execution of our strategy.

I think the one thing that is clear from all the communications, ours, even from the core letter and from our discussion with a lot of other investors, is this is a very valuable portfolio. We've got a lot of great fundamentals that are going to drive our future value creation. Frankly, that is the number one priority. Everybody agrees is execute and drive performance, and that's what's going to create the maximum value in all terms. What our strategy is, our board, just to be clear, we have a very good board already. We've been changing the board for many years now. We have experts from every business that we're in. The board regularly reviews all our strategy. We haven't woken up now because we have an activist or any investor.

We've been doing a lot of our work. I've had these discussions with all of you in terms of our views on the market, the industry changes that are happening, and the opportunities that lie ahead in the coming year. None of that has changed. I think what's changed is we engaged Ancora. We had actually a very constructive discussion. They were constructive, we were constructive. I think everybody understands the businesses, the issues. They came forward with two very strong directors that can add value to our business. They have relevant experience to what we're doing. We saw that as a great opportunity to reinforce the board. We'll have new views that will come into our strategy work. The committee will be reinforced now with some other new views.

We're going to let them do the work that they have been doing and continue to do. We're not going to speculate on what they want to do or not. I think that's their job to make recommendations to the full board of what that process is going to be like. The number one priority that we all agree on is execute, drive the performance, create the optionality of value, organic or inorganic. We want to make sure that we have all options. This is not something that you want to just be forced to do one thing. We want to make sure that we have options to create value in multiple directions with our shareholders.

Okay. As second, just a clarification question. I don't think I've heard about the advanced manufacturing tax credits before in discussing the Intermediates segment. I don't think NMP itself qualifies that's here. This is a derivative effect you're seeing from the battery customers downstream?

William, do you want to?

Yeah. No, John, this is something that we spoke actually this time last year on it. Just as a reminder, it's an incentive around domestic production in some key sectors, one of which is battery. It does improve our cost position. It helps make domestic producers more competitive. The concept itself was introduced a couple of years ago, but the eligibility was more defined in Q3 last year. As you look year-over-year, it's about a $3 million headwind for the Intermediates business, but sequentially it's stable. This is something we'd expect to continue to have and be eligible for through at least 2029, then it continues to phase out from there.

Great. Thank you.

Sure. Mm-hmm.

Thank you. Our next question comes from Josh Spector with UBS. Please go ahead. Your line is now open.

Yeah. Hey, good morning, guys. I want to just follow up on actually one of John's earlier questions around the cost savings and the flow through to 2027. You were pretty clear in your answer. You thought this year could be 200 basis points higher from a margin perspective, so about $40 million in EBITDA there. Your comments on Hopewell actually seem a little bit more encouraging this quarter than maybe the last couple of quarters. Would you expect more of that $40 million to now flow through in 2027? Or is that still kind of a two-year path? I think before it was more flow through might come in 2028.

I think we'll start seeing the flow through, I would say let's talk in quarters. We should start seeing that probably starting the second quarter. I think this fourth quarter and even first quarter, just the way recap works, you're going to have a little bit of noise. That's why we're being a little bit more cautious in it's not just what we do, but how it flows through the P&L today. After that, I think we should start seeing that flow through. Now, there are parts of the Calvert downtime and all that you'll see quicker because we're already in operation. The $40 million parts of it will take a little bit longer. Parts of it will come, but you will start seeing some of the benefits.

Our biggest issue right now focusing on is Hopewell getting the productivity. It's really kilos per hour production of a certain part of our product line that we want to make sure that we're getting the right throughput, the right cost structure as we move forward.

Okay, thanks. If I could just follow up quickly on Specialty Additives. It seems like you're more comfortable or at least confident around volumes there. We've been talking about new wins for a while, but I feel like we haven't seen them. Architectural coatings demand isn't incredibly strong. What's inspiring confidence now for why we'll see stronger volumes over the next kind of few quarters or year?

A quick comment and, Dago, maybe you can comment. The good news there is from what happened in 2024, the markets have stabilized. They're not at the highest level, I would say, but at least they're stable. We're starting to see share gains. Dago will comment on that. There's a lot of actions now that we can start getting that momentum back. Dago, why don't you go region by region and just give us sort of a view of what's happening?

Sure. Yeah, if I go region by region, because of course, architectural coatings is a very regional market. What you'll see in China is that the market is still pretty stable. I would actually say that it's declining on the new construction space. Having said that, in other industrial applications like electronics, are actually doing quite well for us. Really the secret sauce when it comes to China is team execution. We've been able to really convert into dollars all the regional innovation that we're doing in the region. That's really driven by the team. Europe is flat. There is no signs of recovery. This is driven by Germany and by France. Again, here we've been very disciplined, especially when it comes to market share execution. The other big region for us, of course, is North America, and North America remains the $1 million question.

New construction is still pretty slow, we know there is pent-up demand, it will depend on interest rates. Of course, number one, it will depend on consumer sentiment, for us to determine when we're going to see that inflection point. The good news about all the regions is that innovation is advancing. That's a big part of the growth that we're seeing now. Commercial discipline is high, we're being very careful on how we price our products. We're volume pricing our products. Pipeline execution, that's critical for us to outperform the market. That's overall where we are. I will say the markets are stable. architectural coating is really nothing to report. Performance specialty is doing better than expected.

Thank you.

Thank you. Our next question comes from Jeff Zekauskas with JPMorgan. Please go ahead. Your line is now open.

Thanks very much. It sounds like you've tried to optimize your cash flows this year by reducing your operating rates. How much did that penalize your EBITDA so far this year or for the entire year?

Hey, Jeff. Good morning. Yeah, it's a good question. It builds actually on what Guillermo cited on that 200 basis points comment. How I'd anchor that, about $80 million in inventory drawdown. If you point to how much of that is absorption-related impacting EBITDA, it's probably $30 million-$35 million. Really, as we look going into next year, this is the clearest line of sight we have into a margin recovery is producing to demand. It's related to how Guillermo positioned it, but it's very similar. You're right, it did bolster the balance sheet, meaningful inventory drawdown. We don't expect, at the Ashland level, meaningful inventory swings going forward. Of course, the details matter. By product line, we could have some areas that we rebuild and some areas we have inventory above target.

In general, the big inventory fluctuations is what's happened year to date. From here, I would expect it to be stable.

Jeff, this is an area of discipline that we're really changing and you know the history and just inventory. We do not want to drive performance by building inventory, we're going to be much more disciplined on build as demand goes up. I do think there's upside potential for us given that we've brought it down. We're just not going to start producing just to artificially create a result. We're going to balance our actions based on informed views of demand.

Earlier in the call, did you say that there was a turnaround in the Intermediates and solvents business in the fourth quarter? If there is one, is that a meaningful event for you on an EBITDA basis?

No. The turnaround we did was in Hopewell, that we shut down for a period of time because we made investments, equipment to help with some of the process issues that we were having. The plant's back online and producing, and we're monitoring now the production rates as they come up.

Lastly, in the capital allocation committee that has been formed, when would you expect that committee to make a recommendation, or is there no timeframe for that committee?

I'm not going to speculate on this. We have two new directors that just got named. We got to onboard them. There's a lot of work that we need to do to bring them up to speed. The board has been working on our strategy for a long time now, so we're not going to stop at this point in time. It's really bring them up to speed and then let them do their work. I'm not going to speculate on how fast or That's up to them, and what their views, what their recommendations to the board will be.

Okay, great. Thank you.

Thanks.

Thank you. Our next call comes from Laurence Alexander with Jefferies. Please go ahead. Your line is now open.

Hi. I wanted to ask about the feedback you're getting from your customers about the different innovation platforms, not so much the near-term trends with the technology per se. What are they saying about the size of the potential applications and what you would need to deliver for there to perhaps be discussions about either a more aggressive, they help fund capacity or establishment of JVs in some areas where it's appropriate? Is the overall strategy just for Ashland to try and do everything on its own?

I think that's a great question. I'm not going to steal the thunder of our September 17th event. For everybody that wants to hear the full answer, that's the event that you should participate. We feel very excited. Personally, I feel much more confident. I've been on the road visiting our major customers around the world, and we're getting access to a lot more people, technology, marketing people. The whole engagement has changed because now we've validated, I think, the technology. The issue is, can we get the right product or the right formulation that they want to launch? Can we fall into their reformulation plans whenever they do their big brands, be it in Personal Care, be it in coatings or even some of the Life Sciences. The feedback has been very positive.

I can say, hey, the silicone replacement in Personal Care is looking really exciting. Expanding the multifunctional starch, extremely exciting work that we're seeing the feedback very strong and beyond. We were focusing on carbomer replacement, so microplastic, acrylic-based thickeners and all that. The sensorial, there's a lot of other benefits there that people are excited about. Skin, it's not just for hair, but now also in skin. We got both of those markets really moving well. The super wetter is now going to a lot of different markets. One area that we weren't thinking of moving that quickly was in Personal Care. Actually, now we found a home in terms of ethnic hair for applications to be able to wet and condition hair much faster.

As Alessandra mentioned in the Vazo for ag, we have it in the seed coatings, are working now in the oil dispersants. That also very exciting. The super wetter is doing well over there. I'm personally, and I am biased, I'm really excited by the work that Coatings is doing. That really is more of my prior history. The TiO2 spacer technology we're working, very well received by customers. We haven't sampled that one yet because we were getting all the IP. That process is going, I will say, extremely exciting. Just those examples that I mentioned, we're talking about a very big market potential, and that'll be the theme of the meeting. Silicones in Personal Care, it's an $800 million market. There's a lot of opportunity. This is not a $3 million, $4 million opportunity. We're trying to target some big opportunities.

If you look at rheology, acrylic type chemistry, synthetic chemistries, being able to replace that huge opportunity. That's $400 million-$500 million of business that we're going after. TiO2 replacement, if we can get 10%-20% TiO2 efficiency, you can do the math on how much TiO2, in different types of paints and architectural. Ag also very large market. The issue here is scale. What I would add that I'm excited about is, for the external world, we've been talking about the new technology platforms. In the future, you're going to hear us talk about technology platforms because there's a lot of other things now that we are going into our old technology, and we see opportunities to also go after scalable, and especially on the cellulosics area, I think change the game.

Over the next couple of years, how do we move on to new things that we can bring to the technology? Not a lot of innovation in that space for a long time, and I'm very excited about that.

Thank you.

Thank you. Our next question comes from Steven Haynes with Morgan Stanley. Please go ahead. Your line is now open.

Hey, good morning, everyone. Thanks for taking my question. Lot's been covered, so maybe just a quick one on Life Sciences. I think somewhere in the materials, you talked about customer order timing benefiting the quarter. Just to clarify, was that capturing something that was pushed out of the second quarter, or was that pulling forward something from 4Q?

Alessandra, you want to comment?

To some extent from the second quarter. As I mentioned, if you look at across second, third, fourth quarter, we target mid-single digit growth, and that's what we expect looking across the year and across those quarters. We're talking about the fundamentals, right? The market is stable. We are seeing the great momentum with globalize, Innovate, with the growth on injectables, cellulosics portfolios. Definitely it is the underlying fundamentals are there, and the order pattern wasn't no material.

Okay, thank you. Appreciate it.

Thank you. Our next call comes from Abigail Eberts with Wells Fargo. Please go ahead. Your line is now open.

Hi there. Thanks for taking my question. Just wondering if you could speak more regarding the end demand fundamentals you're seeing in the nutrition business and what led to that decline for you specifically.

Nutrition, we talked about the projects we have and working with customers on new applications, with a focus on improving our mix as well, more towards an improved mix. The new wins, they are coming, but they're coming lower than what we anticipated. We see the momentum with the new applications. It's just coming slower than what we anticipated. As we talked about Nutrition in the past, from the non-meat applications, this is a market that hasn't materialized, right? Yet the growth isn't there. We definitely focus on other applications with our Nutrition portfolio. We are seeing that, it's just the wins are coming is lower than what we anticipated. In the third quarter specifically, just looking at Nutrition, the revenue was stable. It was not a decline.

Okay, thank you. Our final question of the day comes from Mike Harrison with Seaport Research Partners. Please go ahead. Your line is now open.

Hi, good morning. Just one from me. I'm curious, in the globalized portion of your strategy, it looks like you're getting good traction with the current round of investments. I believe you made those going back a couple years. I'm curious, do you still see that there are some gaps or areas that are going to be in need of further investments? What could the timing look like on an additional round of globalized investments? Thanks.

I think we've made a lot of the big investments, if you look at it, if I go by business. Microbial Protection, now we have, as Jim said, every region in Brazil, in North America, in Europe, in Asia, we have local supply. That changes. It's not just the fact that we back integrated also on some of the key actives, we got a better cost structure as we go forward. It puts us in a much more competitive position and allows us to formulate locally using local raw materials. There's a lot of benefits to that. Biofunctionals, we now have in Europe. We have capabilities that we're going to add in Brazil, we have capabilities, in China.

The U.S., that would be one that we want to bring in production here too, so that we can work and be closer to our customers. Those are not big investments, but we will bring in that capability at the right time. In tablet coatings, as Alessandra mentioned in her comments, India, that's a big market for us. We should have the new plant. We did the groundbreaking. Middle of next year, we should be in production. Customers are very excited about some of the products that we have been introducing. You got to be local to really play in that area. I would say we made most of the investments already in the injectable side. In Ireland, the investment we made was oversized so that we can continue to build samples.

Now, we are already getting our first commercial sales, and that is starting to ramp up. We are well-positioned there. In the high purity excipients for injectables, sugars, and other products that, cyclodextrin, we made the investment here in the U.S. in Columbus, Ohio, and we are ramping up production there. We are in a good place. Maybe that's something as we grow, we could put in another region in the future, but that would be further out. I would say biofunctionals and the tablet coatings would be the areas that I would see some investments there. Hopefully, the issue is going to be with new technologies coming in. That is the one that we will probably look at investments to globalize those product lines as they commercialize.

Thank you. This concludes the Q&A session. I would now like to turn the call back to Guillermo for any closing remarks. Guillermo?

Thank you everyone for your participation questions. We look forward to connecting with everybody over the coming weeks. Most importantly, I look forward to updating you on September 17th on our webinar on innovation update on the progress that we have made on those new technologies. Look forward to seeing you in the near future. Thank you.

Thank you for your participation in today's conference. This does now conclude the program. You may now disconnect.